Welcome to the Department of Cellular Therapy which is home to one of Europe’s biggest and most modern GMP facilities for cellular products.

  Dag Josefsen, MD PhD, Head of Department

(Group leaders: E.M. Inderberg and S. Wälchli) has the capacity to undertake complete pre-clinical studies for immunotherapeutic molecules such as vaccines and adoptive T cell transfer (TCR, CAR). It possesses the competence to deliver molecular biology products isolated from patient material (TCR), to perform cellular assays and in vivo animal studies. Finally, innovative tools are also developed in collaboration with academy and private companies.

The Immunomonitoring Lab (Head: E.M. Inderberg) is a heritage from the former research group of Prof. G. Gaudernack and was included in the Department of Cellular Therapy in 2012. It participated to both academic and industrial trials, more information can be found here. 

Our labs are located at the Oslo Cancer Cluster Incubator OCCI

ACT-centre aims at facilitating the development of novel advanced therapy medicinal products (ATMP) and make novel therapies available to Norwegian patients. More information can be found here. 

Delighted to announce that we received the Innovation prize 2023 from our TTO (Inven2). DogBite is a collaboration with our friends (and colleagues) from the University of Bergen which we hope will be the first step towards realistic animal models for validation of immunotherapy. More information can be found here: (article in Norwegian but movie in English). We are grateful to Inven2 for their support (and the nice party)!

The winning team: Pascal Gelebart-Sébastien Wälchli-Vibeke Samuelsen Fosse-Emmet McCormack

The supporting team: Sandy Joaquina-Klara Krpina-Christopher Forcados-Shoaib Diaa Ahmed-Alicia Villatoro-Lindsey Scott

Our Unit was nicely represented at the last CIMT meeting:

Sandy                                               Lea

Nadia                                                Alicia

All news